按HIV感染状态分层的心室辅助装置支持的临床结局:一项STS-INTERMACS分析
研究分析INTERMACS注册中22,065例心室辅助装置植入患者,比较85例HIV阳性与21,980例HIV阴性患者的结局。HIV阳性患者更年轻、体重指数更低、既往卒中率更高。匹配队列中,早期植入年份HIV阳性患者死亡率显著更高,但2018-2020年植入年份未见此关联;两组卒中、大出血或严重感染无显著差异。结论认为心室辅助装置治疗是HIV阳性终末期心衰患者的可行治疗选择。
要点
- HIV阳性心室辅助装置患者较HIV阴性患者更年轻(中位年龄58岁 vs 59岁)、体重指数更低(26 kg/m2 vs 29 kg/m2)、既往卒中率更高(8% vs 4%)。
- 匹配队列中,早期植入年份HIV阳性患者死亡率显著更高,但2018-2020年植入年份未见此关联。
- 匹配与非匹配队列中,两组植入后卒中、大出血或严重感染均无显著差异。
核心结论
- 随着机械循环支持和HIV治疗的近期进展,心室辅助装置治疗是HIV阳性终末期心衰患者的可行治疗选择。
研究设计与样本
- 分析INTERMACS注册中22,065例心室辅助装置植入患者,按HIV状态比较结局,并进行调整21项植入前危险因素的倾向性匹配分析。
主要发现
- HIV阳性组85例,HIV阴性组21,980例;HIV阳性组中位年龄58岁 vs 59岁(p=0.02),体重指数26 kg/m2 vs 29 kg/m2(p=0.001),既往卒中8% vs 4%(p=0.02)。
- 匹配的HIV阳性与HIV阴性队列中,早期植入年份HIV阳性患者死亡率显著更高,但2018-2020年植入年份未见此关联。
- 匹配与非匹配队列中,植入后卒中、大出血或严重感染均无显著差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease remains the leading cause of mortality in human immunodeficiency virus-infected (HIV-positive) patients. Ventricular assist device therapy is rarely offered to these patients and data on outcomes are sparse. We investigated outcomes following ventricular assist device implants for HIV-positive as compared to non-HIV-infected (HIV-negative) patients. METHODS: We analyzed 22,065 patients from the Interagency Registry for Mechanically Assisted Circulatory Support registry for outcomes by HIV status. A propensity-matched analysis adjusting for 21 preimplant risk factors was also conducted. RESULTS: Compared with 21,980 HIV-negative device recipients, the 85 HIV-positive recipients were younger (median age 58 years vs 59 years, p = 0.02), had lower body mass index (26 kg/m2 vs 29 kg/m2, p = 0.001), and had higher rates of prior stroke (8% vs 4%, p = 0.02). In the matched HIV-positive and HIV-negative cohorts, there was significantly higher mortality in HIV-positive patients in earlier implant years, however, this association was not seen in later implant years (2018-2020). In both unmatched and matched cohorts, no significant differences in postimplantation stroke, major bleeding, or major infection were noted. CONCLUSIONS: With recent advancements in mechanical circulatory support and HIV treatment, ventricular assist device therapy is a viable therapeutic option for HIV-positive patients with end-stage heart failure.
引用
- Birk SE, Baran DA, Campbell R, et al. Clinical outcomes of ventricular assist device support by HIV infection status: An STS-INTERMACS analysis. J Heart Lung Transplant. 2023. PMID: 37146667. doi:10.1016/j.healun.2023.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。